Neurogene Announce a New Development Program for Rett Syndrome – NGN-401
Today Neurogene announced a new development program for Rett syndrome, NGN-401. NGN-401 is an MECP2 gene therapy candidate using Neurogene’s novel EXACT technology, which was developed in collaboration with the University of Edinburgh. This work at the University of Edinburgh is led by Stuart Cobb, Ph.D., who has been researching Rett syndrome for over 15 years, striving to make a difference for patients and families.
Click here to read Neurogene’s letter to the Rett Syndrome community.
